Aditi Foundation
HomeAboutEventsPhotosStudio animationMohallaGroupsNewsjournalJobsPostsInfo & ads
Other areas
Teesri nazar
Sudhir Tailang "Cartoon Mania"
HAAT – buy Cartoon Products
Our story - Vibha
Fundraising events
Friends list
Recreational ADDA
Gaming video
Crisis response
Filhaal toons
Recent ads act
Here & Now
Weather courtesy Google
Become a partner (E.g. Sponsors)
Commercialisation of institutions
Annual calendar
Sudhir Tailang's
National flag in memory of Sudhir Tailang
Salute - shame
Right to constitutional remedy


Dedicated to My Dear Husband Shri Sudhir Tailang

Home/Business/Recurrent Glioblastoma Multiforme Treatment Market 2019 Analysis and Industry Outlook 2025 Business Recurrent Glioblastoma Multiforme Treatment Market 2019 Analysis and Industry Outlook 2025 Avatar tanmay December 12, 2019

This report on global Recurrent Glioblastoma Multiforme Treatment Market is a detailed research study that helps provides answers and pertinent questions with respect to the emerging trends and growth opportunities in this particular industry. It helps identify each of the prominent barriers to growth, apart from identifying the trends within various application segments of the global market.

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Recurrent Glioblastoma Multiforme Treatment Market: Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, Cantex Pharmaceuticals, Inc., Cavion LLC, Celldex Therapeutics, Inc., Coherus BioSciences, Inc., Cortice Biosciences, Inc., Eisai, Eli Lilly and Company, EnGeneIC LtdERC Band others.

Click the link to get a Sample Copy of the Report before purchase:

Global Recurrent Glioblastoma Multiforme Treatment Market Split By Product Type And Applications:

This report segments the global Recurrent Glioblastoma Multiforme Treatment Market on the basis of Types are:






On the basis of Application, the Global Recurrent Glioblastoma Multiforme Treatment Market is segmented into:




(Special Offer: Get flat 20% discount on this report)

Inquire for Discount:

Regional Analysis For Recurrent Glioblastoma Multiforme Treatment Market:

For comprehensive understanding of market dynamics, the global Recurrent Glioblastoma Multiforme Treatment Market is analysed across key geographies namely: United States, China, Europe, Japan, South-east Asia, India and others. Each of these regions is analysed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Influence of the Recurrent Glioblastoma Multiforme Treatment Market report:

-Comprehensive assessment of all opportunities and risk in the Recurrent Glioblastoma Multiforme Treatment Market.

-Recurrent Glioblastoma Multiforme Treatment Market recent innovations and major events.

-Detailed study of business strategies for growth of the Recurrent Glioblastoma Multiforme Treatment Market-leading players.

 01-Jan-2017 12:00 amComment

Diffusion Pharmaceuticals Presents Data Suggesting Optimized TSC Dosing Regimen Increases Survival in Newly Diagnosed Inoperable Glioblastoma Patients Presentation Made by Chief Scientific Officer John Gainer at the Inaugural Glioblastoma Drug Development Summit

CHARLOTTESVILLE, Va., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, announces the presentation of data signaling increased survival in inoperable glioblastoma multiforme (GBM) patients enrolled in the 19-patient lead-in portion of its open-label, dose-escalation Phase 3 study with Trans Sodium Crocetinate (TSC) plus standard of care (SOC). Chief Scientific Officer John Gainer, Ph.D. presented these findings today at the inaugural Glioblastoma Drug Development Summit in Boston, sponsored by Hanson Wade.

Dr. Gainer’s presentation included earlier research demonstrating that TSC safely reduces tumor hypoxia by a novel mechanism of action, making the tumor up to 3 times more susceptible to radiation and chemotherapy. In Phase 2 testing of TSC in newly diagnosed inoperable GBM patients, a nearly 4-fold increase in 2-year survival was seen compared with historical controls.

The current Phase 3 INTACT (INvestigating Tsc Against Cancerous Tumors) study – an open-label, randomized, controlled trial – was designed to examine this finding in a fully powered safety and efficacy registration study.  The study was further designed to test a new TSC dosing regimen under which, in addition to the 18 injections of TSC administered during the radiation therapy phase, patients receive 18 additional injections of TSC during the post-radiation chemotherapy phase, at doses up to 6-times higher than those received during radiation. The addition of this high-dose regimen was based on research performed by Dr. Gainer over the last three years in his laboratory at Diffusion’s headquarters.

In the randomized portion of the INTACT trial, subjects will be randomized at baseline to SOC for first-line treatment of GBM plus TSC, or to SOC alone. The SOC for GBM is temozolomide plus radiation therapy for 6 weeks, followed by 28 days of rest, then by 6 cycles of post-radiation temozolomide treatment.

In the 19-patient open-label, dose-escalation, lead-in portion of the INTACT trial, safety was demonstrated in all patients receiving TSC at all dosing levels.  Further, the Company believes that, while the number of high dose patients (7) is small, the addition of the 18 higher-dose treatments of TSC may be having a positive effect on survival.  In his talk, Dr. Gainer presented a Kaplan-Meier survival plot highlighting the difference in survival seen with the addition of high-dose TSC treatment compared with both SOC and the earlier Phase 2 study. The current data show an 86% “Fraction Surviving,” with 38% for the completed Phase 2 TSC study and 13% for SOC. 

The ability of patients to perform daily activities as measured by Karnofsky performance scores also increased from baseline following completion of high-dose treatment with TSC, with scores showing a differential of 15% improvement over the Phase 2 results at 18 weeks, which is the time at which a decline rather than an improvement normally occurs.

Dr. Gainer’s slide presentation is available at and includes graphics of these data.

“Even when taking into account the small number of patients enrolled, the difference in results with the new TSC dosing regimen compared with both the former TSC regimen and the standard of care is notable,” said David Kalergis, Diffusion Pharmaceuticals CEO. “We are gratified by the continued clean safety profile of TSC.  We also believe that observed survival differences of this magnitude send a meaningful signal about TSC, further de-risking the INTACT Phase 3 study during the randomized phase.”

Mr. Kalergis continued, “Patients diagnosed with inoperable GBM have a dire prognosis and very limited treatment options.  Given TSC’s proven safety profile and observed efficacy signals, we need to make all efforts to provide a new treatment option to these patients.” 

The Company is seeking a partner to continue development of TSC in the inoperable GBM indication, and has begun patient enrollment in its Phase 2 on-ambulance trial with TSC for the treatment of stroke.

About Hanson Wade

Hanson Wade's goal is to accelerate progress within organizations and across industries. Its primary method for achieving this is by creating exclusive business conferences that gather together the world's smartest thinkers and doers. The inaugural Glioblastoma Drug Development Summit is designed with two critical and ambitious objectives:  to help overcome the major biological challenges limiting effective glioblastoma treatment; and to evaluate novel therapies and innovative trial designs to prevent more tragic Phase 2 failures.

About Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Inc. is an innovative biotechnology company developing new treatments that improve the body’s ability to bring oxygen to the areas where it is needed most, offering new hope for the treatment of life-threatening medical conditions.

Diffusion’s lead drug TSC was originally developed in conjunction with the Office of Naval Research, which was seeking a way to treat hemorrhagic shock caused by massive blood loss on the battlefield. Evolutions in research have led to Diffusion’s focus today: Fueling Life by taking on some of medicine’s most intractable and difficult-to-treat diseases, including stroke and GBM brain cancer. In each of these diseases, hypoxia – oxygen deprivation of essential tissue in the body – has proved to be a significant obstacle for medical providers and is the target for TSC’s novel mechanism.

In July 2019 the Company reported favorable safety data in a 19-patient dose-escalation run-in study to its Phase 3 INTACT program, using TSC to target inoperable GBM.  Further findings from the dose-escalation run-in study, released in December 2019, also showed signals of enhanced survival and patient performance.  Diffusion’s on-ambulance PHAST-TSC trial for acute stroke has begun patient enrollment. In addition, preclinical data supports the potential for TSC as a treatment for other conditions where hypoxia plays a major role, such as myocardial infarction, respiratory diseases such as COPD, peripheral artery disease, and neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease.

Further, RES-529, the Company’s PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes, is in preclinical testing for GBM.

Diffusion is headquartered in Charlottesville, Virginia – a hub of advancement in the life science and biopharmaceutical industries – and is led by CEO David Kalergis, a 30-year industry veteran and company co-founder.

Forward-Looking Statements

To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the company's plans, objectives, expectations  and intentions with respect to future operations and products, the potential of the company's technology and product candidates, the anticipated timing of future clinical trials, and other statements that are not historical in nature, particularly those that utilize terminology such as "would," "will," "plans," "possibility," "potential," "future," "expects," "anticipates," "believes," "intends," "continue," "expects," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause the Diffusion’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular uncertainties and risks include: the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; general business and economic conditions; the company's need for and ability to obtain additional financing or partnering arrangements; and the various risk factors (many of which are beyond Diffusion’s control) as described under the heading “Risk Factors” in Diffusion’s filings with the United States Securities and Exchange Commission. All forward-looking statements in this news release speak only as of the date of this news release and are based on management's current beliefs and expectations. Diffusion undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

 01-Jan-2017 12:00 amComment

DECEMBER 12, 2019 Ultrasound blasts potent glioblastoma drug into brain tumor by Northwestern University

One of most potent drugs for treatment of glioblastoma, the most deadly type of brain tumor, can't be used in patients because of two problems. First, it can't reach its target because it's blocked by the blood-brain barrier, a microscopic structure that protects the brain from toxins in the blood. And the conventional formulation for this drug is toxic to the brain.

But now Northwestern Medicine scientists have used a novel technology for opening the blood-brain barrier with an implantable ultrasound, and have delivered the powerful drug to the tumor in mice. In a new paper, they report on their findings of extensive preclinical research.

The scientists also discovered brain toxicity for the conventional formulation for this drug—paclitaxel -to the brain was caused by the solution required to dissolve the drug (cremophor.) Scientists tested a new formulation of the drug that uses albumin as opposed to cremophor, and it was not harmful to the brain.

Opening of the blood-brain barrier with an ultrasound increased the concentrations of this paclitaxel in the brain by five-fold. The study also showed that the brain tumor-bearing mice live much longer when treated with the powerful cancer-fighting drug paclitaxel, and survival was even further extended when treated in combination with ultrasound to open the blood-brain barrier.

The study will be published Dec. 12 in Clinical Cancer Research, a journal of the American Association for Cancer Research. 

In the laboratory, paclitaxel is much more potent than the currently used chemotherapy temozolomide. When paclitaxel was tested against the brain tumor in a dish outside an organism, a 1,400-fold lesser drug concentration was necessary to kill same number of tumor cells, compared to the conventional chemotherapy used for this cancer.

The scientists are now applying to the U.S. Food & Drug Administration to launch a clinical trial to test this concept of a new formulation of paclitaxel in combination with the novel ultrasound technology to open the blood-brain barrier in patients. The planned trial aims to determine if the treatment is safe, and if it prolongs survival of patients with brain cancer.

"Glioblastoma currently has no cure, and when the tumor recurs there are not many treatment options," said the principal investigator for this study, Dr. Adam Sonabend, an assistant professor of neurological surgery at Northwestern University Feinberg School of Medicine and a Northwestern Medicine physician. "We urgently need effective new treatments."

The ultrasound technology may have broader benefits. "This ultrasound technology now will enable us to use many agents established in other cancers for patients with brain tumors," said co-investigator Roger Stupp, chief of neuro-oncology and the Paul C. Bucy Professor of Neurological Surgery at Feinberg.

Other clinical trials are testing ultrasound-based opening of the blood brain barrier with various chemotherapy agents, but none are using such a potent drug as paclitaxel.

How does it work?

The tiny ultrasound would be implanted during surgery into a window in the skull that does not contain bone. It is used in combination with microscopic gas bubbles injected into the blood at the same time the ultrasound begins. When the bubbles hit the sound waves, these vibrate and mechanically disrupt the blood-brain barrier. The opening is immediate, allowing penetration of the drug molecules. The blood-brain barrier opening is reversible and lasts for several hours after the sonication. The ultrasound emitter remains in the skull for repeated delivery of the drug.

Explore further

Improving drug delivery for brain tumor treatment

More information: Daniel Y. Zhang et al. Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations Clinical Cancer Research. Published OnlineFirst December 12, 2019. DOI: 10.1158/1078-0432.CCR-19-2182

Journal information: Clinical Cancer Research

 01-Jan-2017 12:00 amComment

... Contd  
Photo feature
Sudhir Tailang's cartoon of the month
International cartoons watch
Security watch
Crime watch
Media watch
Health watch
Education watch
Book watch
Entertainment watch
Event watch
Adolescent problems
Human rights watch
Walk free
Development watch
Sports watch
Travel watch
State watch
Country watch
Continent watch
Political watch
Right to satire
Legal watch
Spirituality watch
Environment watch
Tech watch
Sudhir Tailang roadmap
Pro-poor watch
Grievances cell - Let's talk
Tribute to Sudhir Tailang
Home City Bikaner
Sudhir TailangHealthCancerCartoons in educationDonationsContactLoginMy Account